What is the current Gene Therapy in Oncology market size?

The Gene Therapy in Oncology market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Gene Therapy in Oncology market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Gene Therapy in Oncology market?

Key drivers include rising cancer incidence and advancements in gene editing technologies, fueling future outlook.

What are the major challenges facing the Gene Therapy in Oncology market?

Challenges include high development costs, regulatory hurdles, and limited patient access to novel therapies.

Which regions are expected to lead the Gene Therapy in Oncology market?

North America and Europe are expected to dominate, driven by strong research ecosystems and investment.

Who are the top companies in the Gene Therapy in Oncology market?

Leading companies include Novartis, Gilead Sciences, and bluebird bio, driving innovation and growth.

What future opportunities exist in the Gene Therapy in Oncology market?

Emerging opportunities include combination therapies, personalized medicine, and expanding into new cancer types.

How will technology impact the Gene Therapy in Oncology market?

Advances in CRISPR technology and gene editing will significantly impact the market, enabling more precise treatments.

What is the current regulatory landscape for Gene Therapy in Oncology?

Regulatory frameworks are evolving, with ongoing efforts to streamline approval processes and ensure patient safety.

How will the Gene Therapy in Oncology market evolve in the next 5 years?

The market will experience significant growth, driven by increasing adoption of gene therapies and expanding treatment options.

Gene Therapy in Oncology Strategic Analysis & Growth Outlook 2033

Gene Therapy in Oncology by Type (/> Ex Vivo, In Vivo), by Application (/> Hospitals, Diagnostics Centers, Research Institutes), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gene Therapy in Oncology Market Overview

The Gene Therapy in Oncology market refers to the use of gene therapy to treat cancer, which has become a crucial aspect of cancer treatment in recent years. As the Gene Therapy in Oncology market size is expected to grow significantly, it is essential to understand the growth outlook, market forecast, and industry expansion. The scope of this market includes various types of gene therapies, such as ex vivo and in vivo gene therapies, and their applications in treating different types of cancer. With a current market size of approximately $1.4 billion, the Gene Therapy in Oncology market is anticipated to experience a CAGR of around 24% from 2026 to 2033, driven by macro drivers such as increasing cancer prevalence, advancements in gene editing technologies, and rising investments in oncology research.

Loading chart…

The Gene Therapy in Oncology market is shaped by key forces such as technology shifts, including the development of new gene editing tools like CRISPR, regulations, such as those related to clinical trials and product approvals, and competitive intensity, driven by the entry of new players in the market. The largest region in the Gene Therapy in Oncology market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in healthcare infrastructure and research. As the market continues to evolve, it is essential for stakeholders to stay informed about the latest developments and trends shaping the Gene Therapy in Oncology market forecast.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol-Myers Squibb; Cold Genesys; Advantagene; Amgen; AstraZeneca; Bio-Path Holdings; CRISPR Therapeutics; Editas Medicine; Geron Corp; Idera Pharmaceuticals; Intellia Therapeutics; Johnson & Johnson; Marsala Biotech; Merck; Mologen AG; Oncolytics Biotech; Oncosec; Oncotelic; Shenzhen SiBiono GeneTech; Sillajen Biotherapeutics; Tocagen; UniQure; Ziopharm Oncology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gene Therapy in Oncology market is poised for significant growth, driven by advances in technology and increasing demand for innovative cancer treatments. The Gene Therapy in Oncology market size is expected to expand rapidly, with a promising growth forecast. Key dynamics shaping the market include:

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR/Cas9, are enabling the development of more precise and effective gene therapies for cancer treatment

Increasing investment in research and development, coupled with rising partnerships between pharmaceutical companies and research institutions, is driving innovation in the Gene Therapy in Oncology market

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Gene Therapy in Oncology market

Concerns over the safety and efficacy of gene therapies, including the risk of off-target effects and immune reactions, are constraining market growth

Opportunities2 items

The increasing prevalence of cancer and the need for more effective treatments are creating opportunities for gene therapy companies to develop innovative products

The Gene Therapy in Oncology market is expected to benefit from the rising adoption of precision medicine approaches, which emphasize targeted and personalized treatments

Challenges2 items

The complex and time-consuming process of developing and commercializing gene therapies is a significant challenge for companies in the Gene Therapy in Oncology market

Pricing and reimbursement issues, including the high cost of gene therapies and limited insurance coverage, are limiting patient access to these treatments

Market Segmentation

Loading chart…

The Type segment in the Gene Therapy in Oncology market refers to the different approaches used to introduce, remove, or change genetic material within a patient's cells to fight cancer. This segment is crucial in understanding the Gene Therapy in Oncology segmentation as it directly impacts the market size. The type segment includes various subtypes, such as gene editing, gene expression, and gene transfer, each contributing to the overall market growth.

The Application segment in the Gene Therapy in Oncology market involves the use of gene therapy for the treatment of various types of cancer. This segment plays a vital role in market taxonomy as it helps in identifying the potential applications of gene therapy in oncology. The application segment includes subtypes such as lung cancer, breast cancer, and leukemia, among others, each holding a significant share in the overall Gene Therapy in Oncology market size.

Gene Therapy in Oncology Segmentation Breakdown7 items

Type

/> Ex Vivo

In Vivo

Application

/> Hospitals

Diagnostics Centers

Research Institutes

Regional Insights

Loading chart…

The Gene Therapy in Oncology market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of gene therapy, favorable policies, and significant investments in the region.

Key drivers for North America include a mature ecosystem, high infrastructure development, and a large patient population. In Europe, drivers include a strong regulatory framework, increasing demographics with cancer, and growing investments in gene therapy research. Asia Pacific's growth is driven by a large and growing patient population, increasing awareness of gene therapy, and rising healthcare expenditure. Latin America's growth is driven by improving access to healthcare, increasing awareness of gene therapy, and growing investments in the region. The Middle East & Africa region is driven by growing demand for innovative cancer treatments, increasing investments in healthcare infrastructure, and a rising ecosystem maturity.

The regional forecast indicates that these regions will continue to play a significant role in the Gene Therapy in Oncology market growth, with each region presenting unique opportunities and challenges. Understanding these regional dynamics is crucial for stakeholders to navigate the market effectively and capitalize on emerging trends.

Competitive Landscape

The Gene Therapy in Oncology market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The Gene Therapy in Oncology competitive landscape is characterized by high competition, with companies focusing on differentiation through innovative products and services. Companies are adopting various strategies to gain a competitive edge, including investments in research and development, strategic partnerships, and expansion into new markets.

Companies in the Gene Therapy in Oncology market are employing common strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are focusing on specific strategic areas:

Bristol-Myers Squibb: regional expansion

Cold Genesys: innovation pipeline

Advantagene: premium pricing

Amgen: vertical integration

AstraZeneca: OEM tie-ups

CRISPR Therapeutics: local manufacturing

Key Gene Therapy in Oncology Companies23 items

Bristol-Myers Squibb

Cold Genesys

Advantagene

Amgen

AstraZeneca

Bio-Path Holdings

CRISPR Therapeutics

Editas Medicine

Geron Corp

Idera Pharmaceuticals

Intellia Therapeutics

Johnson & Johnson

Marsala Biotech

Merck

Mologen AG

Oncolytics Biotech

Oncosec

Oncotelic

Shenzhen SiBiono GeneTech

Sillajen Biotherapeutics

Tocagen

UniQure

Ziopharm Oncology

Market Ecosystem

The Gene Therapy in Oncology ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. Value is created and captured through the development, integration, and delivery of gene therapies, with various stakeholders contributing to the overall process. The ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where technologies are integrated and products are manufactured; and downstream, where products are distributed and delivered to end users.

Raw material/component suppliers — providing genetic materials

Technology providers — developing gene editing tools

OEMs / manufacturers — producing gene therapy products

System integrators / EPCs — integrating gene therapies into treatment protocols

Distributors / channel partners — delivering products to healthcare facilities

Regulators/standards bodies — establishing guidelines and approvals

End users / buyers — administering gene therapies to patients

In the Gene Therapy in Oncology ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the approval and adoption of gene therapies. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, including those related to manufacturing and testing. Switching costs and partnerships are also critical, as companies may need to form alliances to access specific technologies or expertise. Furthermore, the ecosystem differs by region, with varying regulatory frameworks and reimbursement models affecting the flow of value and the interactions among participants, highlighting the need for a nuanced value chain analysis to understand the complex dynamics at play.

Recent Industry Insights

The Gene Therapy in Oncology industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and biotechnology firms, have accelerated the development of innovative gene therapies for cancer treatment. Notable mergers and acquisitions have also taken place, enabling companies to expand their portfolios and strengthen their positions in the market. Furthermore, several product and technology launches have occurred, including the introduction of new gene editing tools and vectors, which have enhanced the efficacy and safety of gene therapies.

In addition, regulatory changes have supported the growth of the Gene Therapy in Oncology industry, with authorities implementing more flexible and adaptive approval processes for gene therapies. The shift in consumer and enterprise trends towards more personalized and targeted therapies has also driven the demand for gene therapies in oncology. Moreover, funding rounds and expansions have increased, providing companies with the necessary resources to advance their research and development efforts, ultimately shaping the future of the Gene Therapy in Oncology industry trends.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Gene Therapy in Oncology market outlook. The market attractiveness is high due to the increasing prevalence of cancer and the growing demand for innovative treatments. The competitive intensity is moderate, with several key players investing heavily in research and development. The long-term outlook is promising, with a strong innovation landscape driven by advancements in technology and a rising demand for personalized medicine.

The demand-supply balance is expected to be stable, with an increasing number of approvals and launches of new gene therapies. However, key risk factors include regulatory challenges, high development costs, and reimbursement issues. Overall, the Gene Therapy in Oncology market is poised for significant growth, driven by its potential to transform the treatment of cancer and improve patient outcomes.

11 items

1. Executive Summary

2. Gene Therapy in Oncology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gene Therapy in Oncology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gene Therapy in Oncology Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Ex Vivo

6.1.2. In Vivo

6.2. Global Gene Therapy in Oncology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Diagnostics Centers

6.2.3. Research Institutes

6.3. Global Gene Therapy in Oncology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gene Therapy in Oncology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gene Therapy in Oncology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Gene Therapy in Oncology Market Competition by Key Manufacturers

8.1. Global Gene Therapy in Oncology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gene Therapy in Oncology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bristol-Myers Squibb

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cold Genesys

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Advantagene

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Amgen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AstraZeneca

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Path Holdings

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CRISPR Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Editas Medicine

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Geron Corp

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Idera Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Intellia Therapeutics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Johnson & Johnson

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Marsala Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Merck

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Mologen AG

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Oncolytics Biotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Oncosec

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Oncotelic

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Shenzhen SiBiono GeneTech

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Sillajen Biotherapeutics

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Tocagen

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. UniQure

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Ziopharm Oncology

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gene Therapy in Oncology Market

Figure 4: Global Gene Therapy in Oncology Market: Drivers

Figure 5: Global Gene Therapy in Oncology Market: Challenges

Figure 6: Global Gene Therapy in Oncology Market: Trends

Figure 7: Global Gene Therapy in Oncology Market: Opportunity

Figure 8: Global Gene Therapy in Oncology Market: Restraint

Figure 9: Global Gene Therapy in Oncology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Gene Therapy in Oncology Market Value (USD Million) By Region

Figure 15: Global Gene Therapy in Oncology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Gene Therapy in Oncology Market Value (USD Million) By Region

Figure 23: Global Gene Therapy in Oncology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Gene Therapy in Oncology Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Gene Therapy in Oncology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Gene Therapy in Oncology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Gene Therapy in Oncology Market Value (USD Million) By Region

Table 10: Global Gene Therapy in Oncology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Gene Therapy in Oncology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gene Therapy in Oncology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gene Therapy in Oncology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bristol-Myers Squibb Basic Information And Sales Area

Table 31: Bristol-Myers Squibb. Products Portfolio

Table 32: Cold Genesys Basic Information And Sales Area

Table 33: Cold Genesys. Products Portfolio

Table 34: Advantagene Basic Information And Sales Area

Table 35: Advantagene. Products Portfolio

Table 36: Amgen Basic Information And Sales Area

Table 37: Amgen. Products Portfolio

Table 38: AstraZeneca Basic Information And Sales Area

Table 39: AstraZeneca. Products Portfolio

Table 40: Bio-Path Holdings Basic Information And Sales Area

Table 41: Bio-Path Holdings. Products Portfolio

Table 42: CRISPR Therapeutics Basic Information And Sales Area

Table 43: CRISPR Therapeutics. Products Portfolio

Table 44: Editas Medicine Basic Information And Sales Area

Table 45: Editas Medicine. Products Portfolio

Table 46: Geron Corp Basic Information And Sales Area

Table 47: Geron Corp. Products Portfolio

Table 48: Idera Pharmaceuticals Basic Information And Sales Area

Table 49: Idera Pharmaceuticals. Products Portfolio

Table 50: Intellia Therapeutics Basic Information And Sales Area

Table 51: Intellia Therapeutics. Products Portfolio

Table 52: Johnson & Johnson Basic Information And Sales Area

Table 53: Johnson & Johnson. Products Portfolio

Table 54: Marsala Biotech Basic Information And Sales Area

Table 55: Marsala Biotech. Products Portfolio

Table 56: Merck Basic Information And Sales Area

Table 57: Merck. Products Portfolio

Table 58: Mologen AG Basic Information And Sales Area

Table 59: Mologen AG. Products Portfolio

Table 60: Oncolytics Biotech Basic Information And Sales Area

Table 61: Oncolytics Biotech. Products Portfolio

Table 62: Oncosec Basic Information And Sales Area

Table 63: Oncosec. Products Portfolio

Table 64: Oncotelic Basic Information And Sales Area

Table 65: Oncotelic. Products Portfolio

Table 66: Shenzhen SiBiono GeneTech Basic Information And Sales Area

Table 67: Shenzhen SiBiono GeneTech. Products Portfolio

Table 68: Sillajen Biotherapeutics Basic Information And Sales Area

Table 69: Sillajen Biotherapeutics. Products Portfolio

Table 70: Tocagen Basic Information And Sales Area

Table 71: Tocagen. Products Portfolio

Table 72: UniQure Basic Information And Sales Area

Table 73: UniQure. Products Portfolio

Table 74: Ziopharm Oncology Basic Information And Sales Area

Table 75: Ziopharm Oncology. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Type

Table 77: Global Market Share (%) By Type (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Application

Table 79: Global Market Share (%) By Application (2032)

Table 80: Global Gene Therapy in Oncology Market Value (USD Million) By Region

Table 81: Global Gene Therapy in Oncology Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Type

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Type

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Type

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Gene Therapy in Oncology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol-Myers Squibb; Cold Genesys; Advantagene; Amgen; AstraZeneca; Bio-Path Holdings; CRISPR Therapeutics; Editas Medicine; Geron Corp; Idera Pharmaceuticals; Intellia Therapeutics; Johnson & Johnson; Marsala Biotech; Merck; Mologen AG; Oncolytics Biotech; Oncosec; Oncotelic; Shenzhen SiBiono GeneTech; Sillajen Biotherapeutics; Tocagen; UniQure; Ziopharm Oncology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR/Cas9, are enabling the development of more precise and effective gene therapies for cancer treatment

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Gene Therapy in Oncology market

Concerns over the safety and efficacy of gene therapies, including the risk of off-target effects and immune reactions, are constraining market growth

Opportunities2 items

The increasing prevalence of cancer and the need for more effective treatments are creating opportunities for gene therapy companies to develop innovative products

The Gene Therapy in Oncology market is expected to benefit from the rising adoption of precision medicine approaches, which emphasize targeted and personalized treatments

Challenges2 items

The complex and time-consuming process of developing and commercializing gene therapies is a significant challenge for companies in the Gene Therapy in Oncology market

Pricing and reimbursement issues, including the high cost of gene therapies and limited insurance coverage, are limiting patient access to these treatments

Market Segmentation

Loading chart…

Gene Therapy in Oncology Segmentation Breakdown7 items

Type

/> Ex Vivo

In Vivo

Application

/> Hospitals

Diagnostics Centers

Research Institutes

Regional Insights

Loading chart…

Competitive Landscape

Bristol-Myers Squibb: regional expansion

Cold Genesys: innovation pipeline

Advantagene: premium pricing

Amgen: vertical integration

AstraZeneca: OEM tie-ups

CRISPR Therapeutics: local manufacturing

Key Gene Therapy in Oncology Companies23 items

Bristol-Myers Squibb

Cold Genesys

Advantagene

Amgen

AstraZeneca

Bio-Path Holdings

CRISPR Therapeutics

Editas Medicine

Geron Corp

Idera Pharmaceuticals

Intellia Therapeutics

Johnson & Johnson

Marsala Biotech

Merck

Mologen AG

Oncolytics Biotech

Oncosec

Oncotelic

Shenzhen SiBiono GeneTech

Sillajen Biotherapeutics

Tocagen

UniQure

Ziopharm Oncology

Market Ecosystem

Raw material/component suppliers — providing genetic materials

Technology providers — developing gene editing tools

OEMs / manufacturers — producing gene therapy products

System integrators / EPCs — integrating gene therapies into treatment protocols

Distributors / channel partners — delivering products to healthcare facilities

Regulators/standards bodies — establishing guidelines and approvals

End users / buyers — administering gene therapies to patients

Recent Industry Insights

Analyst Overview

Table of Contents